Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk - PubMed
3 hours ago
- #lipid-lowering therapies
- #Bayesian network meta-analysis
- #diabetic kidney disease
- Cerivastatin was most effective at reducing total cholesterol (TC) in diabetic kidney disease (DKD).
- Simvastatin was most effective at lowering low-density lipoprotein cholesterol (LDL-C) in DKD.
- Atorvastatin, Rosuvastatin, and Fenofibrate showed potential to improve urine albumin-to-creatinine ratio (UACR).
- Atorvastatin and Fenofibrate most robustly reduced cardiovascular event rates (CVER) in hyperlipidemic DKD.
- The study supports a phenotype-driven Cardio-Renal-Metabolic (CRM) strategy prioritizing cardiovascular risk reduction.